mobile-logo
 

All News

05 Aug

Professor Mark Middleton appointed to Physiomics SAB

by Charmaine Fraser
in Other News
Comments

Physiomics plc is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford. He is an eminent clinician with highly relevant clinical experience. Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research...

Read More
28 Apr

Workshop on Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science- June 2, 2015, Hersonissos (Greece)

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics will present a half-day workshop on “Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science”, ahead of the 2015 PAGE meeting. This workshop will review the preclinical Virtual Tumour model used to predict optimal doses and schedules of combination therapy. We will provide an overview regarding the recent extension of the current model to include immunotherapy and clinical translational. This will then be...

Read More
22 Apr

Physiomics to present new developments of the Virtual Tumour platform in immunotherapy at AACR Annual Meeting 2015

by Charmaine Fraser
in Other News
Comments

Physiomics plc is pleased to announce that it is participating in the American Association for Cancer Research Annual Meeting 2015, taking place at the Pennsylvania Convention Center, Philadelphia, Pennsylvania on 18-22 April 2015. Dr Frances Brightman will present on the application of the Virtual Tumour platform to predict agents targeting the PD-1/PD-L1 axis in combination with radiotherapy. ...

Read More
03 Mar

First contract for a clinical version of our Virtual Tumour model (“Virtual Tumour Clinical”) with Global Pharmaceutical Company, Merck (Merck Serono)

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono, the biopharmaceutical division of Merck, Germany. Revenue from the contract will fall in the 2014/2015 and 2015/2016 financial years and is in the region of the total value of all of Physiomics 2013/2014 sales. As such it...

Read More
12 Nov

Final Results for the year ended 30 June 2014

by Charmaine Fraser
in Investor News / RNS
Comments

Chairman’s Statement   Summary of Results in the year ended 30 June 2014   The turnover of the Company increased by 12% to £267,903 (2013: £240,000). The operating loss reduced by 15% to £465,265 (2013: £548,342). On 30 June 2014 the surplus of shareholders’ funds was £136,487 (2013: £255,821). This year, Physiomics has made good progress advancing Virtual Tumour Clinical and has broadened its offering into the personalised medicine...

Read More
04 Nov

Disclosure of Large Pharma partner Merck & Co.

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is delighted to announce that Merck & Co., a top 5 pharmaceutical company, has disclosed that it is a customer of Physiomics.   Merck & Co. published a paper in CPT: Pharmacometrics and Systems Biology (part of Nature Group) in which Virtual Tumour was specified as a technology which had helped their decision-making process...

Read More
27 Oct

Update: 4th extension project to advance oncology candidate with global pharma company

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further extension to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012.  The extension will cover predicting optimal regimens for a further candidate compound and should be completed by the end of 2014...

Read More